Pancreatic Cancer Research

ResearcherUniversity of PaviaActive in the last 2 years

Carlo R. Lazzaro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4795-1834; OpenAlex author ID A5032116339. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers

Papers 3

  1. On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alon… Co-author DOI 10.1177/17588359241276812↗
  2. Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancre… Co-author DOI 10.1186/s42506-024-00179-3↗
  3. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the… Co-author DOI 10.1080/14737167.2018.1464394↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carlo Antonio Barone · 1 shared paper, 2018 · strength 0.08
  2. Evaristo Maiello · 1 shared paper, 2018 · strength 0.08
  3. Giampaolo Tortora · 1 shared paper, 2018 · strength 0.08
  4. Michèle Milella · 1 shared paper, 2018 · strength 0.08
  5. Michele Reni · 1 shared paper, 2018 · strength 0.08
  6. Stefano Cascinu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.